http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 02 Jul 2026 07:25:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Kane+Biotech+Announces+Results+of+Annual+and+Special+Meeting+of+Shareholders/26723993.html <p align="justify">WINNIPEG, Manitoba, July 02, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) the voting results from its annual and special meeting of shareholders (the “Meeting”) on June 24, 2026.</p> <p align="justify">A total of 83,622,028 common shares were represented at the Meeting, representing approximately 46% of the Company’s issued and outstanding common shares (“Common Shares”) as of the record date of the Meeting.</p> <p align="justify">All matters voted upon at the Meeting were approved by shareholders, as detailed below.</p> <p align="justify"><strong>Election of Directors</strong></p> <p align="justify">All six nominees listed in http://www.streetinsider.com/Press+Releases/Kane+Biotech+Announces+Results+of+Annual+and+Special+Meeting+of+Shareholders/26723993.html Thu, 02 Jul 2026 07:25:00 -0400 A.17150087 A.30400265 A.36078215 KNBIF KNE O.02540339 O.02555813 O.34929518 O.49066140 http://www.streetinsider.com/Press+Releases/Kane+Biotech+Announces+Results+of+Annual+and+Special+Meeting+of+Shareholders/26723993.html <p align="justify">WINNIPEG, Manitoba, July 02, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) the voting results from its annual and special meeting of shareholders (the “Meeting”) on June 24, 2026.</p> <p align="justify">A total of 83,622,028 common shares were represented at the Meeting, representing approximately 46% of the Company’s issued and outstanding common shares (“Common Shares”) as of the record date of the Meeting.</p> <p align="justify">All matters voted upon at the Meeting were approved by shareholders, as detailed below.</p> <p align="justify"><strong>Election of Directors</strong></p> <p align="justify">All six nominees listed in http://www.streetinsider.com/Press+Releases/Kane+Biotech+Announces+Results+of+Annual+and+Special+Meeting+of+Shareholders/26723993.html Thu, 02 Jul 2026 07:25:00 -0400 A.17150087 A.30400265 A.36078215 KNBIF KNE O.02540339 O.02555813 O.34929518 O.49066140 http://www.streetinsider.com/Press+Releases/Kane+Biotech+Announces+Results+of+Annual+and+Special+Meeting+of+Shareholders/26723993.html <p align="justify">WINNIPEG, Manitoba, July 02, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) the voting results from its annual and special meeting of shareholders (the “Meeting”) on June 24, 2026.</p> <p align="justify">A total of 83,622,028 common shares were represented at the Meeting, representing approximately 46% of the Company’s issued and outstanding common shares (“Common Shares”) as of the record date of the Meeting.</p> <p align="justify">All matters voted upon at the Meeting were approved by shareholders, as detailed below.</p> <p align="justify"><strong>Election of Directors</strong></p> <p align="justify">All six nominees listed in http://www.streetinsider.com/Press+Releases/Kane+Biotech+Announces+Results+of+Annual+and+Special+Meeting+of+Shareholders/26723993.html Thu, 02 Jul 2026 07:25:00 -0400 A.17150087 A.30400265 A.36078215 KNBIF KNE O.02540339 O.02555813 O.34929518 O.49066140 http://www.streetinsider.com/Press+Releases/Kane+Biotech+Announces+Results+of+Annual+and+Special+Meeting+of+Shareholders/26723993.html <p align="justify">WINNIPEG, Manitoba, July 02, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) the voting results from its annual and special meeting of shareholders (the “Meeting”) on June 24, 2026.</p> <p align="justify">A total of 83,622,028 common shares were represented at the Meeting, representing approximately 46% of the Company’s issued and outstanding common shares (“Common Shares”) as of the record date of the Meeting.</p> <p align="justify">All matters voted upon at the Meeting were approved by shareholders, as detailed below.</p> <p align="justify"><strong>Election of Directors</strong></p> <p align="justify">All six nominees listed in http://www.streetinsider.com/Press+Releases/Kane+Biotech+Announces+Results+of+Annual+and+Special+Meeting+of+Shareholders/26723993.html Thu, 02 Jul 2026 07:25:00 -0400 A.17150087 A.30400265 A.36078215 KNBIF KNE O.02540339 O.02555813 O.34929518 O.49066140 http://www.streetinsider.com/Press+Releases/Kane+Biotech+Announces+Results+of+Annual+and+Special+Meeting+of+Shareholders/26723993.html <p align="justify">WINNIPEG, Manitoba, July 02, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) the voting results from its annual and special meeting of shareholders (the “Meeting”) on June 24, 2026.</p> <p align="justify">A total of 83,622,028 common shares were represented at the Meeting, representing approximately 46% of the Company’s issued and outstanding common shares (“Common Shares”) as of the record date of the Meeting.</p> <p align="justify">All matters voted upon at the Meeting were approved by shareholders, as detailed below.</p> <p align="justify"><strong>Election of Directors</strong></p> <p align="justify">All six nominees listed in http://www.streetinsider.com/Press+Releases/Kane+Biotech+Announces+Results+of+Annual+and+Special+Meeting+of+Shareholders/26723993.html Thu, 02 Jul 2026 07:25:00 -0400 A.17150087 A.30400265 A.36078215 KNBIF KNE O.02540339 O.02555813 O.34929518 O.49066140 http://www.streetinsider.com/Press+Releases/Kane+Biotech+Announces+Results+of+Annual+and+Special+Meeting+of+Shareholders/26723993.html <p align="justify">WINNIPEG, Manitoba, July 02, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) the voting results from its annual and special meeting of shareholders (the “Meeting”) on June 24, 2026.</p> <p align="justify">A total of 83,622,028 common shares were represented at the Meeting, representing approximately 46% of the Company’s issued and outstanding common shares (“Common Shares”) as of the record date of the Meeting.</p> <p align="justify">All matters voted upon at the Meeting were approved by shareholders, as detailed below.</p> <p align="justify"><strong>Election of Directors</strong></p> <p align="justify">All six nominees listed in http://www.streetinsider.com/Press+Releases/Kane+Biotech+Announces+Results+of+Annual+and+Special+Meeting+of+Shareholders/26723993.html Thu, 02 Jul 2026 07:25:00 -0400 A.17150087 A.30400265 A.36078215 KNBIF KNE O.02540339 O.02555813 O.34929518 O.49066140 http://www.streetinsider.com/Press+Releases/Kane+Biotech+Announces+Results+of+Annual+and+Special+Meeting+of+Shareholders/26723993.html <p align="justify">WINNIPEG, Manitoba, July 02, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) the voting results from its annual and special meeting of shareholders (the “Meeting”) on June 24, 2026.</p> <p align="justify">A total of 83,622,028 common shares were represented at the Meeting, representing approximately 46% of the Company’s issued and outstanding common shares (“Common Shares”) as of the record date of the Meeting.</p> <p align="justify">All matters voted upon at the Meeting were approved by shareholders, as detailed below.</p> <p align="justify"><strong>Election of Directors</strong></p> <p align="justify">All six nominees listed in http://www.streetinsider.com/Press+Releases/Kane+Biotech+Announces+Results+of+Annual+and+Special+Meeting+of+Shareholders/26723993.html Thu, 02 Jul 2026 07:25:00 -0400 A.17150087 A.30400265 A.36078215 KNBIF KNE O.02540339 O.02555813 O.34929518 O.49066140 http://www.streetinsider.com/Press+Releases/Kane+Biotech+Announces+Results+of+Annual+and+Special+Meeting+of+Shareholders/26723993.html <p align="justify">WINNIPEG, Manitoba, July 02, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) the voting results from its annual and special meeting of shareholders (the “Meeting”) on June 24, 2026.</p> <p align="justify">A total of 83,622,028 common shares were represented at the Meeting, representing approximately 46% of the Company’s issued and outstanding common shares (“Common Shares”) as of the record date of the Meeting.</p> <p align="justify">All matters voted upon at the Meeting were approved by shareholders, as detailed below.</p> <p align="justify"><strong>Election of Directors</strong></p> <p align="justify">All six nominees listed in http://www.streetinsider.com/Press+Releases/Kane+Biotech+Announces+Results+of+Annual+and+Special+Meeting+of+Shareholders/26723993.html Thu, 02 Jul 2026 07:25:00 -0400 A.17150087 A.30400265 A.36078215 KNBIF KNE O.02540339 O.02555813 O.34929518 O.49066140 http://www.streetinsider.com/Press+Releases/Kane+Biotech+Announces+Results+of+Annual+and+Special+Meeting+of+Shareholders/26723993.html <p align="justify">WINNIPEG, Manitoba, July 02, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) the voting results from its annual and special meeting of shareholders (the “Meeting”) on June 24, 2026.</p> <p align="justify">A total of 83,622,028 common shares were represented at the Meeting, representing approximately 46% of the Company’s issued and outstanding common shares (“Common Shares”) as of the record date of the Meeting.</p> <p align="justify">All matters voted upon at the Meeting were approved by shareholders, as detailed below.</p> <p align="justify"><strong>Election of Directors</strong></p> <p align="justify">All six nominees listed in http://www.streetinsider.com/Press+Releases/Kane+Biotech+Announces+Results+of+Annual+and+Special+Meeting+of+Shareholders/26723993.html Thu, 02 Jul 2026 07:25:00 -0400 A.17150087 A.30400265 A.36078215 KNBIF KNE O.02540339 O.02555813 O.34929518 O.49066140 http://www.streetinsider.com/Globe+Newswire/Kane+Biotech+Announces+Results+of+Annual+and+Special+Meeting+of+Shareholders/26723993.html <p align="justify">WINNIPEG, Manitoba, July 02, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) the voting results from its annual and special meeting of shareholders (the “Meeting”) on June 24, 2026.</p> <p align="justify">A total of 83,622,028 common shares were represented at the Meeting, representing approximately 46% of the Company’s issued and outstanding common shares (“Common Shares”) as of the record date of the Meeting.</p> <p align="justify">All matters voted upon at the Meeting were approved by shareholders, as detailed below.</p> <p align="justify"><strong>Election of Directors</strong></p> <p align="justify">All six nominees listed in http://www.streetinsider.com/Globe+Newswire/Kane+Biotech+Announces+Results+of+Annual+and+Special+Meeting+of+Shareholders/26723993.html Thu, 02 Jul 2026 07:25:00 -0400 A.17150087 A.30400265 A.36078215 KNBIF KNE O.02540339 O.02555813 O.34929518 O.49066140 http://www.streetinsider.com/Globe+Newswire/Kane+Biotech+Announces+Results+of+Annual+and+Special+Meeting+of+Shareholders/26723993.html <p align="justify">WINNIPEG, Manitoba, July 02, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) the voting results from its annual and special meeting of shareholders (the “Meeting”) on June 24, 2026.</p> <p align="justify">A total of 83,622,028 common shares were represented at the Meeting, representing approximately 46% of the Company’s issued and outstanding common shares (“Common Shares”) as of the record date of the Meeting.</p> <p align="justify">All matters voted upon at the Meeting were approved by shareholders, as detailed below.</p> <p align="justify"><strong>Election of Directors</strong></p> <p align="justify">All six nominees listed in http://www.streetinsider.com/Globe+Newswire/Kane+Biotech+Announces+Results+of+Annual+and+Special+Meeting+of+Shareholders/26723993.html Thu, 02 Jul 2026 07:25:00 -0400 A.17150087 A.30400265 A.36078215 KNBIF KNE O.02540339 O.02555813 O.34929518 O.49066140 http://www.streetinsider.com/Globe+Newswire/Kane+Biotech+Announces+Results+of+Annual+and+Special+Meeting+of+Shareholders/26723993.html <p align="justify">WINNIPEG, Manitoba, July 02, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) the voting results from its annual and special meeting of shareholders (the “Meeting”) on June 24, 2026.</p> <p align="justify">A total of 83,622,028 common shares were represented at the Meeting, representing approximately 46% of the Company’s issued and outstanding common shares (“Common Shares”) as of the record date of the Meeting.</p> <p align="justify">All matters voted upon at the Meeting were approved by shareholders, as detailed below.</p> <p align="justify"><strong>Election of Directors</strong></p> <p align="justify">All six nominees listed in http://www.streetinsider.com/Globe+Newswire/Kane+Biotech+Announces+Results+of+Annual+and+Special+Meeting+of+Shareholders/26723993.html Thu, 02 Jul 2026 07:25:00 -0400 A.17150087 A.30400265 A.36078215 KNBIF KNE O.02540339 O.02555813 O.34929518 O.49066140 http://www.streetinsider.com/Globe+Newswire/Kane+Biotech+Announces+Results+of+Annual+and+Special+Meeting+of+Shareholders/26723993.html <p align="justify">WINNIPEG, Manitoba, July 02, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) the voting results from its annual and special meeting of shareholders (the “Meeting”) on June 24, 2026.</p> <p align="justify">A total of 83,622,028 common shares were represented at the Meeting, representing approximately 46% of the Company’s issued and outstanding common shares (“Common Shares”) as of the record date of the Meeting.</p> <p align="justify">All matters voted upon at the Meeting were approved by shareholders, as detailed below.</p> <p align="justify"><strong>Election of Directors</strong></p> <p align="justify">All six nominees listed in http://www.streetinsider.com/Globe+Newswire/Kane+Biotech+Announces+Results+of+Annual+and+Special+Meeting+of+Shareholders/26723993.html Thu, 02 Jul 2026 07:25:00 -0400 A.17150087 A.30400265 A.36078215 KNBIF KNE O.02540339 O.02555813 O.34929518 O.49066140 http://www.streetinsider.com/Globe+Newswire/Kane+Biotech+Announces+Results+of+Annual+and+Special+Meeting+of+Shareholders/26723993.html <p align="justify">WINNIPEG, Manitoba, July 02, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) the voting results from its annual and special meeting of shareholders (the “Meeting”) on June 24, 2026.</p> <p align="justify">A total of 83,622,028 common shares were represented at the Meeting, representing approximately 46% of the Company’s issued and outstanding common shares (“Common Shares”) as of the record date of the Meeting.</p> <p align="justify">All matters voted upon at the Meeting were approved by shareholders, as detailed below.</p> <p align="justify"><strong>Election of Directors</strong></p> <p align="justify">All six nominees listed in http://www.streetinsider.com/Globe+Newswire/Kane+Biotech+Announces+Results+of+Annual+and+Special+Meeting+of+Shareholders/26723993.html Thu, 02 Jul 2026 07:25:00 -0400 A.17150087 A.30400265 A.36078215 KNBIF KNE O.02540339 O.02555813 O.34929518 O.49066140 http://www.streetinsider.com/Globe+Newswire/Kane+Biotech+Announces+Results+of+Annual+and+Special+Meeting+of+Shareholders/26723993.html <p align="justify">WINNIPEG, Manitoba, July 02, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) the voting results from its annual and special meeting of shareholders (the “Meeting”) on June 24, 2026.</p> <p align="justify">A total of 83,622,028 common shares were represented at the Meeting, representing approximately 46% of the Company’s issued and outstanding common shares (“Common Shares”) as of the record date of the Meeting.</p> <p align="justify">All matters voted upon at the Meeting were approved by shareholders, as detailed below.</p> <p align="justify"><strong>Election of Directors</strong></p> <p align="justify">All six nominees listed in http://www.streetinsider.com/Globe+Newswire/Kane+Biotech+Announces+Results+of+Annual+and+Special+Meeting+of+Shareholders/26723993.html Thu, 02 Jul 2026 07:25:00 -0400 A.17150087 A.30400265 A.36078215 KNBIF KNE O.02540339 O.02555813 O.34929518 O.49066140 http://www.streetinsider.com/Globe+Newswire/Kane+Biotech+Announces+Results+of+Annual+and+Special+Meeting+of+Shareholders/26723993.html <p align="justify">WINNIPEG, Manitoba, July 02, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) the voting results from its annual and special meeting of shareholders (the “Meeting”) on June 24, 2026.</p> <p align="justify">A total of 83,622,028 common shares were represented at the Meeting, representing approximately 46% of the Company’s issued and outstanding common shares (“Common Shares”) as of the record date of the Meeting.</p> <p align="justify">All matters voted upon at the Meeting were approved by shareholders, as detailed below.</p> <p align="justify"><strong>Election of Directors</strong></p> <p align="justify">All six nominees listed in http://www.streetinsider.com/Globe+Newswire/Kane+Biotech+Announces+Results+of+Annual+and+Special+Meeting+of+Shareholders/26723993.html Thu, 02 Jul 2026 07:25:00 -0400 A.17150087 A.30400265 A.36078215 KNBIF KNE O.02540339 O.02555813 O.34929518 O.49066140 http://www.streetinsider.com/Globe+Newswire/Kane+Biotech+Announces+Results+of+Annual+and+Special+Meeting+of+Shareholders/26723993.html <p align="justify">WINNIPEG, Manitoba, July 02, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) the voting results from its annual and special meeting of shareholders (the “Meeting”) on June 24, 2026.</p> <p align="justify">A total of 83,622,028 common shares were represented at the Meeting, representing approximately 46% of the Company’s issued and outstanding common shares (“Common Shares”) as of the record date of the Meeting.</p> <p align="justify">All matters voted upon at the Meeting were approved by shareholders, as detailed below.</p> <p align="justify"><strong>Election of Directors</strong></p> <p align="justify">All six nominees listed in http://www.streetinsider.com/Globe+Newswire/Kane+Biotech+Announces+Results+of+Annual+and+Special+Meeting+of+Shareholders/26723993.html Thu, 02 Jul 2026 07:25:00 -0400 A.17150087 A.30400265 A.36078215 KNBIF KNE O.02540339 O.02555813 O.34929518 O.49066140 http://www.streetinsider.com/Globe+Newswire/Kane+Biotech+Announces+Results+of+Annual+and+Special+Meeting+of+Shareholders/26723993.html <p align="justify">WINNIPEG, Manitoba, July 02, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) the voting results from its annual and special meeting of shareholders (the “Meeting”) on June 24, 2026.</p> <p align="justify">A total of 83,622,028 common shares were represented at the Meeting, representing approximately 46% of the Company’s issued and outstanding common shares (“Common Shares”) as of the record date of the Meeting.</p> <p align="justify">All matters voted upon at the Meeting were approved by shareholders, as detailed below.</p> <p align="justify"><strong>Election of Directors</strong></p> <p align="justify">All six nominees listed in http://www.streetinsider.com/Globe+Newswire/Kane+Biotech+Announces+Results+of+Annual+and+Special+Meeting+of+Shareholders/26723993.html Thu, 02 Jul 2026 07:25:00 -0400 A.17150087 A.30400265 A.36078215 KNBIF KNE O.02540339 O.02555813 O.34929518 O.49066140 http://www.streetinsider.com/Press+Releases/Kane+Biotech+Announces+First+Quarter+2026+Financial+Results/26567662.html <p align="justify">WINNIPEG, Manitoba, May 28, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) announces today its first quarter 2026 financial results.</p> <p align="justify"><strong>First Quarter 2026 Financial Highlights: </strong></p> <ul><li style="text-align:justify;">Total revenue for the three months ended March 31, 2026 was $43,218 compared to $412,513 in three months ended March 31, 2025. Revenue in the period reflects early-stage commercialization of revyve wound gel alongside the liquidation of the Company’s DermaKB® product line. The prior-year period included legacy animal health operations, underscoring the Company’s transition to a focused human wound care strategy. http://www.streetinsider.com/Press+Releases/Kane+Biotech+Announces+First+Quarter+2026+Financial+Results/26567662.html Thu, 28 May 2026 17:05:00 -0400 A.17150087 A.36078215 A.40958841 KNBIF KNE O.02540339 O.02555813 O.34929518 O.36670513 http://www.streetinsider.com/Press+Releases/Kane+Biotech+Announces+First+Quarter+2026+Financial+Results/26567662.html <p align="justify">WINNIPEG, Manitoba, May 28, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) announces today its first quarter 2026 financial results.</p> <p align="justify"><strong>First Quarter 2026 Financial Highlights: </strong></p> <ul><li style="text-align:justify;">Total revenue for the three months ended March 31, 2026 was $43,218 compared to $412,513 in three months ended March 31, 2025. Revenue in the period reflects early-stage commercialization of revyve wound gel alongside the liquidation of the Company’s DermaKB® product line. The prior-year period included legacy animal health operations, underscoring the Company’s transition to a focused human wound care strategy. http://www.streetinsider.com/Press+Releases/Kane+Biotech+Announces+First+Quarter+2026+Financial+Results/26567662.html Thu, 28 May 2026 17:05:00 -0400 A.17150087 A.36078215 A.40958841 KNBIF KNE O.02540339 O.02555813 O.34929518 O.36670513 http://www.streetinsider.com/Press+Releases/Kane+Biotech+Announces+First+Quarter+2026+Financial+Results/26567662.html <p align="justify">WINNIPEG, Manitoba, May 28, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) announces today its first quarter 2026 financial results.</p> <p align="justify"><strong>First Quarter 2026 Financial Highlights: </strong></p> <ul><li style="text-align:justify;">Total revenue for the three months ended March 31, 2026 was $43,218 compared to $412,513 in three months ended March 31, 2025. Revenue in the period reflects early-stage commercialization of revyve wound gel alongside the liquidation of the Company’s DermaKB® product line. The prior-year period included legacy animal health operations, underscoring the Company’s transition to a focused human wound care strategy. http://www.streetinsider.com/Press+Releases/Kane+Biotech+Announces+First+Quarter+2026+Financial+Results/26567662.html Thu, 28 May 2026 17:05:00 -0400 A.17150087 A.36078215 A.40958841 KNBIF KNE O.02540339 O.02555813 O.34929518 O.36670513 http://www.streetinsider.com/Press+Releases/Kane+Biotech+Announces+First+Quarter+2026+Financial+Results/26567662.html <p align="justify">WINNIPEG, Manitoba, May 28, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) announces today its first quarter 2026 financial results.</p> <p align="justify"><strong>First Quarter 2026 Financial Highlights: </strong></p> <ul><li style="text-align:justify;">Total revenue for the three months ended March 31, 2026 was $43,218 compared to $412,513 in three months ended March 31, 2025. Revenue in the period reflects early-stage commercialization of revyve wound gel alongside the liquidation of the Company’s DermaKB® product line. The prior-year period included legacy animal health operations, underscoring the Company’s transition to a focused human wound care strategy. http://www.streetinsider.com/Press+Releases/Kane+Biotech+Announces+First+Quarter+2026+Financial+Results/26567662.html Thu, 28 May 2026 17:05:00 -0400 A.17150087 A.36078215 A.40958841 KNBIF KNE O.02540339 O.02555813 O.34929518 O.36670513 http://www.streetinsider.com/Press+Releases/Kane+Biotech+Announces+First+Quarter+2026+Financial+Results/26567662.html <p align="justify">WINNIPEG, Manitoba, May 28, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) announces today its first quarter 2026 financial results.</p> <p align="justify"><strong>First Quarter 2026 Financial Highlights: </strong></p> <ul><li style="text-align:justify;">Total revenue for the three months ended March 31, 2026 was $43,218 compared to $412,513 in three months ended March 31, 2025. Revenue in the period reflects early-stage commercialization of revyve wound gel alongside the liquidation of the Company’s DermaKB® product line. The prior-year period included legacy animal health operations, underscoring the Company’s transition to a focused human wound care strategy. http://www.streetinsider.com/Press+Releases/Kane+Biotech+Announces+First+Quarter+2026+Financial+Results/26567662.html Thu, 28 May 2026 17:05:00 -0400 A.17150087 A.36078215 A.40958841 KNBIF KNE O.02540339 O.02555813 O.34929518 O.36670513 http://www.streetinsider.com/Press+Releases/Kane+Biotech+Announces+First+Quarter+2026+Financial+Results/26567662.html <p align="justify">WINNIPEG, Manitoba, May 28, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) announces today its first quarter 2026 financial results.</p> <p align="justify"><strong>First Quarter 2026 Financial Highlights: </strong></p> <ul><li style="text-align:justify;">Total revenue for the three months ended March 31, 2026 was $43,218 compared to $412,513 in three months ended March 31, 2025. Revenue in the period reflects early-stage commercialization of revyve wound gel alongside the liquidation of the Company’s DermaKB® product line. The prior-year period included legacy animal health operations, underscoring the Company’s transition to a focused human wound care strategy. http://www.streetinsider.com/Press+Releases/Kane+Biotech+Announces+First+Quarter+2026+Financial+Results/26567662.html Thu, 28 May 2026 17:05:00 -0400 A.17150087 A.36078215 A.40958841 KNBIF KNE O.02540339 O.02555813 O.34929518 O.36670513 http://www.streetinsider.com/Press+Releases/Kane+Biotech+Announces+First+Quarter+2026+Financial+Results/26567662.html <p align="justify">WINNIPEG, Manitoba, May 28, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) announces today its first quarter 2026 financial results.</p> <p align="justify"><strong>First Quarter 2026 Financial Highlights: </strong></p> <ul><li style="text-align:justify;">Total revenue for the three months ended March 31, 2026 was $43,218 compared to $412,513 in three months ended March 31, 2025. Revenue in the period reflects early-stage commercialization of revyve wound gel alongside the liquidation of the Company’s DermaKB® product line. The prior-year period included legacy animal health operations, underscoring the Company’s transition to a focused human wound care strategy. http://www.streetinsider.com/Press+Releases/Kane+Biotech+Announces+First+Quarter+2026+Financial+Results/26567662.html Thu, 28 May 2026 17:05:00 -0400 A.17150087 A.36078215 A.40958841 KNBIF KNE O.02540339 O.02555813 O.34929518 O.36670513